Modified BPaL Regimen for Managing Pre-XDR TB and MDR (TI/NR) TB in India

Launched by TUBERCULOSIS RESEARCH CENTRE, INDIA · Sep 1, 2021

Keywords

ClinConnect Summary

This clinical trial is testing a new treatment called the modified BPaL regimen for patients with difficult-to-treat forms of tuberculosis (TB), specifically those with pre-extensively drug-resistant TB (pre-XDR TB) and multidrug-resistant TB (MDR TB) who cannot tolerate standard treatments. The goal is to see if a shorter, all-oral treatment can improve patient outcomes, reduce side effects, and make it easier for patients to stick to their treatment plans. This could help lower costs for patients and improve their overall health.

To participate in the trial, individuals must be adults aged 18 to 65 years with confirmed pre-XDR or MDR TB and meet other health criteria, such as having a stable body weight and good liver function. Participants will need to provide consent and may undergo some testing, including checking for HIV and heart health. Throughout the study, they can expect close monitoring to ensure their safety and well-being as they receive the new treatment. This trial is currently active but not recruiting new participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adults aged between 18 years - 65 years
• • 2. Pulmonary Pre-XDR-TB, patients \[with documented evidence of resistance to rifampicin with or without isoniazid resistance AND additional resistance to any fluoroquinolones by conventional DST (culture-based1) or rapid DST (Xpert MTB/RIF or Trunat MTB/RIF or LPA) from a certified laboratory\] OR MDR-TBTI/NR patients \[with documented treatment intolerance or non-response to MDR TB treatment regimen for 6-months or more when the participant was adherent to the treatment regimen\]
• • 3. Bodyweight of ≥30 kg (in light clothing and no shoes)
• • 4. Provide written, informed consent before all study-related procedures
• • 5. Provide consent to HIV testing2 (if an HIV test was performed within 1 month before the study start, it should not be repeated as long as documentation can be provided \[ELISA and/or Western Blot\]).
• • 6. Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) \< 2.5 x ULN; Total bilirubin lesser than ULN when accompanied by an increase in other liver function tests.
• • 7. QTcF less than or equal to 450 at baseline
• • 8. Female patients should not be pregnant or should be using a birth control method. They should be willing to continue practicing birth control methods (barrier or non-barrier contraceptive methods including oral contraceptives) throughout the treatment period, or history of post-menopausal for the past 12 months.
• Exclusion Criteria:
• • Non-DST based criteria
• • 1. Intolerance or risk of toxicity from medicine in the treatment regimens (e.g. drug-drug interactions)
• • 2. Patient who has received more than 2 weeks of Bedaquiline or Linezolid before the first dose of BPaL regimen
• • 3. Pregnancy or Lactating women
• • 4. All forms of Extrapulmonary TB (Lymph node TB associated with Pulmonary DR-TB and pleural effusion associated with pulmonary TB can be considered for inclusion )
• • 5. HIV infected patient having a CD4+ cell count of ≤ 50 cells/µL;
• • 6. Currently having an uncontrolled cardiac arrhythmia that requires medication
• 7. Have any of the following QTcF interval characteristics at screening:
• • 1. QTcF ≥ 450 at baseline \& normal electrolytes, ECG to be repeated after 6 hours and if both ECGs show QTc\>450 then the patient should not be challenged with cardiotoxic drugs.
• • 2. History of additional risk factors for Torsade de Pointes, e.g. heart failure, hypokalaemia, family history of long QT syndrome;
• • 8. Any condition in the Investigator's opinion (i.e., an unstable disease such as uncontrolled diabetes on insulin3 or cardiomyopathy), where participation would compromise the well-being of the patient or prevent, limit or confound protocol-specified assessments.
• • 9. Very seriously ill patients (Karnofsky scores \< 50 within last 30 days)
• • 10. If results of the serum chemistry panel or, hematology are outside the normal reference range (as given below), the patient may still be considered if the physician judges that the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable.
• • Hypokalaemia, hypomagnesemia, and hypocalcemia should be corrected before a patient receiving any cardiotoxic drugs. (hypothyroidism is not exclusion criteria, to be considered with simultaneous thyroxine replacement therapy and close monitoring)
• • Haemoglobin level of \< 9.0 g/dl or Platelet count \<1,00,000 /mm3
• • Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) \>2.5 x ULN; Total bilirubin greater ULN when accompanied by an increase in other liver function tests
• • 11. Grade III or IV peripheral neuropathy
• • DST based criteria
• • a. if the result for DST (FQ, LZD)4 is not available and h/o more than 2 weeks consumption of drugs used in the study regimen